BioCentury | Nov 4, 2020

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

Novartis’ former CEO Joe Jimenez and NIBR head Mark Fishman believe that pairing digital technology with drug development in large underserved indications can provide a solid investment model and expedite...
BioCentury | Jun 19, 2020
Product Development

Hua shows sustained benefit in diabetics with glucokinase activator

Hua announced Phase III follow-up data showing its first-in-class diabetes therapy led to sustained HbA1c reductions at one year -- a long-term effect that EVP and CFO George Lin told BioCentury hasn’t been observed with...
BioCentury | Dec 19, 2019

Negative allosteric modulators of glutamate receptor subtypes mGluR2 and mGluR3

DISEASE CATEGORY: Neurology INDICATION: Depression Negative allosteric modulators of the glutamate receptor subtypes mGluR2 and mGluR3 could treat depression. Depression is characterized by reduced active coping mechanisms, intentional measures taken to lower stress, and more...
BioCentury | Dec 13, 2019

NanoDimension backs sight-restoring therapy developer Arctos in series A

Newly launched Arctos will use CHF8 million in series A money to conduct preclinical work on a vector-delivered technology it believes can restore eyesight in patients whose retinal cells have degenerated, rather than those whose...
BioCentury | Nov 13, 2019
Product Development

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by the limitations of previous compounds. Yet...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Sep 18, 2019
Distillery Therapeutics

SLC7A11 and mGluR5 identified as targets for hepatic alcoholic steatosis

DISEASE CATEGORY: Hepatic INDICATION: Liver disease Inhibiting SLC7A11, which excretes glutamate from cells, or the glutamate receptor mGluR5 could treat alcoholic steatosis of the liver. Patients with alcoholic fatty liver disease had elevated plasma levels...
BioCentury | Jan 11, 2019
Clinical News

Aevi's AEVI-001 misses in Phase II for children with ADHD ADHD patients with an mGluR copy number variant (Part A; n=69) and without an mGluR...
...Data" ). Aevi Genomic Medicine Inc. (NASDAQ:GNMX), Wayne, Pa. Product: AEVI-001 Business: Neurology Molecular target: Metabotropic glutamate receptors... week six Status: Phase II data Milestone: NA Brian Moy AEVI-001, MDGN-001, NFC-1 Aevi Genomic Medicine Inc. Metabotropic glutamate receptors (mGluR) Attention...
BioCentury | Oct 3, 2018
Distillery Therapeutics


INDICATION: Parkinson’s disease (PD) Cell culture and rat studies identified a positive allosteric modulator (PAM) of mGluR4 that could help treat catalepsy in PD. Optimization and testing in human mGluR4-expressing CHO cells of a previously...
BioCentury | Jul 10, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Gold-based nanoparticles could be used to deliver CRISPR-Cas9 and CRISPR-Cas12a constructs for neurological diseases. The nanoparticles are generated by conjugating gold nanoparticles to DNA oligonucleotides that bind to the CRISPR endonuclease and single-guide...
Items per page:
1 - 10 of 279